Typhoid Vaccine Market is Expected to Reach the Valuation of USD 719.77 Million by 2029
Data Bridge Market Research recently revealed a comprehensive market intelligence study on the Typhoid Vaccine Market. The newly published report features an appealing format with visually captivating tables, graphs, charts, and figures. These well-incorporated visual elements aim to enhance the accuracy and precision of the presented information, providing readers with a comprehensive understanding of the subject matter.
The Typhoid Vaccine market research report offers the Typhoid Vaccine industry highly developed insights and analyses, providing maximum benefits. By leveraging state-of-the-art tools and techniques for data collection, research, analysis, and estimation, this report ensures accuracy and reliability. The market analysis within the report highlights various segments expected to experience rapid growth according to the estimated forecast frame. Key industry trends, market size, market share estimates, and sales volume are illuminated in the Typhoid Vaccine report, empowering the Typhoid Vaccine industry to strategize and enhance return on investment (ROI). Furthermore, the report covers essential factors such as Growth Opportunity Assessment (GOA), Customer Insights (CI), Competitive Business Intelligence (CBI), and Distribution Channel Assessment (DCA).
Data Bridge Market Research analyses that the typhoid vaccine market was valued at USD 321.48 million in 2021 and is expected to reach USD 719.77 million by 2029, registering a CAGR of 10.6% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Get a Sample Copy of The Typhoid Vaccine Market report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-typhoid-vaccine-market&Aniket
Taking into account historic data, present and future market trends, environmental factors, technological innovations, and progress in related industries, the Typhoid Vaccine report provides valuable information to the Typhoid Vaccine industry. Through competitor analysis, the report grants insights into the strategies employed by key players in the market, including new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions. The Typhoid Vaccine market report caters to diverse markets in line with the specific requirements of the Typhoid Vaccine industry. By doing so, it extracts the most excellent solutions and detailed information about market trends, aiding in informed decision-making and successful outcomes.
Drivers
- Rise in the prevalence of typhoid
The surging prevalence of typhoid in various emerging economies is a major factor driving the typhoid vaccine market’s growth rate during the forecast period of 2022 to 2029. According to estimates from the International Health Metrics and Evaluation (IHME), over 12 million cases of typhoid fever were reported worldwide in 2016, resulting in around 130,000 deaths. The risk of typhoid is increased among people who do not have access to clean water and sanitation. Poor communities and vulnerable people, such as children, are particularly vulnerable.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of typhoid vaccine market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
The report outlines the involvement of key players, including:
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- bioMérieux SA (France)
- Amgen Inc. (US)
Know More about This Premium Research Report @ https://www.databridgemarketresearch.com/reports/global-typhoid-vaccine-market?Aniket
Key Market Segmentation
Type
- Live Attenuated Vaccine
- Monovalent Typhoid Vaccines
- Capsular Polysaccharide Vaccines
- Conjugate Vaccine
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Specialty Clinics
- Homecare
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The Typhoid Vaccine market report includes the following countries in different regions:
North America: United States, Canada, and Mexico.
Europe: Germany, France, United Kingdom, Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and other European countries.
Asia-Pacific (APAC): China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and other Asia-Pacific countries.
Middle East and Africa (MEA): Saudi Arabia, United Arab Emirates (U.A.E), South Africa, Egypt, Israel, and other countries in the Middle East and Africa region.
South America: Brazil, Argentina, and other countries in South America.
These regions represent a comprehensive coverage of key markets, providing a global perspective on the market landscape.
North America dominates the typhoid vaccine market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the ‘market’s growth rate in this region. Additionally, increasing patient awareness and high demand of vaccine will further propel the ‘market’s growth rate in this region
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to surging prevalence of typhoid diseases and favourable regulatory guidelines in this region. Also, the development of healthcare infrastructure and rising government initiatives for immunization programs will further propel the market’market’s growth rate in this region.
TABLE OF CONTENTS
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Research Methodology
Part 04: Market Landscape
Part 05: Pipeline Analysis
Part 06: Market Sizing
Part 07: Five Forces Analysis
Part 08: Market Segmentation
Part 09: Customer Landscape
Part 10: Regional Landscape
Part 11: Decision Framework
Part 12: Drivers And Challenges
Part 13: Market Trends
Part 14: Vendor Landscape
Part 15: Vendor Analysis
Part 16: Appendix
Get the Complete Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-typhoid-vaccine-market&Aniket
Browse More Reports:
https://www.databridgemarketresearch.com/reports/global-atrial-fibrillation-market?AM
https://www.databridgemarketresearch.com/reports/global-dermatoscope-market?AM
https://www.databridgemarketresearch.com/reports/global-laparotomy-sponges-market?AM
https://www.databridgemarketresearch.com/reports/global-personalized-cell-therapeutic-market?AM
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.
Contact Us
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com
Editor Details
-
Company:
- The Wire Times
